Chronic renal insufficiency in children: The 2001 Annual Report of the NAPRTCS

被引:145
作者
Seikaly, MG
Ho, PL
Emmett, L
Fine, RN
Tejani, A
机构
[1] NAPRTCS, Hawthorne, NY 10532 USA
[2] Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA
[3] EMMES Corp, Rockville, MD USA
[4] New York Med Coll, Valhalla, NY 10595 USA
[5] SUNY Stony Brook, Stony Brook, NY 11794 USA
关键词
chronic renal failure; etiology; treatment;
D O I
10.1007/s00467-003-1158-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
End-stage renal disease (ESRD) is a major cause of morbidity in children. Besides its high cost to society, ESRD carries significant mortality. Chronic renal insufficiency (CRI) often precedes ESRD. Identifying factors that correlate with the rate of progression to ESRD is beneficial in the management of children with CRI. Since 1994 the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) has extended its registry to include children with CRI, defined as creatinine clearance (C-Cr) <75 ml/min per 1.73 m(2). As of January 2001, our database registered 4,666 children (<20 years of age) with CRI. Data analysis showed that at least 40% of patients entered had congenital urological anomalies; 39% of patients were followed for at least 3 years. Follow-up data showed that 31% of all registered patients progressed to ESRD by the end of the reporting period. There was a correlation between CRI and several co-morbid clinical factors: low hematocrit, hypoalbuminemia, hypocalcemia, hyperphosphatemia, and hyperparathyroidism, and the rate of progression to ESRD. Primary clinical diagnosis and the age at entry into registry were additional factors that correlated with the rate of progression to ESRD. The main cause of hospitalization in this registry was infection, which accounted for 45% of hospital admissions. Growth delay measured by standard deviation score at baseline was -1.40 at the time of registration. Our data suggest potential areas of improved care that could impact the onset of ESRD.
引用
收藏
页码:796 / 804
页数:9
相关论文
共 44 条
[1]   Malnutrition, cardiac disease, and mortality:: An integrated point of view [J].
Bergström, J ;
Lindholm, B .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :834-841
[2]   LOW-DOSE SUBCUTANEOUS RECOMBINANT ERYTHROPOIETIN IN CHILDREN WITH CHRONIC-RENAL-FAILURE [J].
BURKE, JR .
PEDIATRIC NEPHROLOGY, 1995, 9 (05) :558-561
[3]  
Campbell JD, 1989, DIALYSIS TRANSPLANT, V18, P660
[4]   THERAPY OF RENAL ANEMIA IN CHILDREN AND ADOLESCENTS WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) [J].
CAMPOS, A ;
GARIN, EH .
CLINICAL PEDIATRICS, 1992, 31 (02) :94-99
[5]  
CHAN JCM, 1981, INT J PED NEPHROL, V2, P201
[6]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[7]   Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency [J].
Culleton, BF ;
Larson, MG ;
Wilson, PWF ;
Evans, JC ;
Parfrey, PS ;
Levy, D .
KIDNEY INTERNATIONAL, 1999, 56 (06) :2214-2219
[8]   Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins [J].
Deuther-Conrad, W ;
Franke, S ;
Sommer, M ;
Henle, T ;
Stein, G .
KIDNEY INTERNATIONAL, 2001, 59 :S63-S66
[9]   EFFECT OF HUMAN RECOMBINANT ERYTHROPOIETIN ON BLEEDING-TIME, PLATELET NUMBER AND FUNCTION IN CHILDREN WITH END-STAGE RENAL-DISEASE MAINTAINED BY HEMODIALYSIS [J].
FABRIS, F ;
CORDIANO, I ;
RANDI, ML ;
CASONATO, A ;
MONTINI, G ;
ZACCHELLO, G ;
GIROLAMI, A .
PEDIATRIC NEPHROLOGY, 1991, 5 (02) :225-228
[10]   GROWTH AFTER RECOMBINANT HUMAN GROWTH-HORMONE TREATMENT IN CHILDREN WITH CHRONIC-RENAL-FAILURE - REPORT OF A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY [J].
FINE, RN ;
KOHAUT, EC ;
BROWN, D ;
PERLMAN, AJ .
JOURNAL OF PEDIATRICS, 1994, 124 (03) :374-382